TRVI Executive Compensation
* In USD (Original Currency)
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
---|---|---|---|---|---|---|---|---|
2023-05-01 | 2021 | Thomas Sciascia, M.D. Chief Scientific Officer | 378,788 | 113,050 | 0 | 0 | 7,808 | 717,544 |
2023-05-01 | 2022 | Thomas Sciascia, M.D. Chief Scientific Officer | 391,458 | 130,772 | 0 | 0 | 8,245 | 577,295 |
2023-05-01 | 2022 | David J. Clark, M.D., MBChB | 54,231 | 0 | 0 | 0 | 0 | 580,781 |
2023-05-01 | 2021 | Jennifer Good President and Chief Executive Officer | 505,961 | 216,750 | 0 | 0 | 8,700 | 1,527,439 |
2023-05-01 | 2022 | Jennifer Good President and Chief Executive Officer | 523,182 | 249,518 | 0 | 0 | 9,150 | 898,095 |
2022-04-29 | 2021 | Jennifer Good President and Chief Executive Officer | 505,961 | 216,750 | 0 | 0 | 8,700 | 1,527,439 |
2022-04-29 | 2020 | Jennifer Good President and Chief Executive Officer | 477,692 | 176,400 | 0 | 0 | 8,550 | 1,441,457 |
2022-04-29 | 2021 | William Forbes, Pharm. D. | 406,731 | 153,000 | 0 | 0 | 0 | 1,180,794 |
2022-04-29 | 2021 | Thomas Sciascia, M.D. Chief Medical Officer | 378,788 | 113,050 | 0 | 0 | 7,808 | 717,544 |
2022-04-29 | 2020 | Thomas Sciascia, M.D. Chief Medical Officer | 368,577 | 99,725 | 0 | 0 | 7,948 | 709,894 |
2021-04-27 | 2020 | Jennifer Good President and Chief Executive Officer | 477,692 | 176,400 | 0 | 0 | 8,550 | 1,441,457 |
2021-04-27 | 2019 | Jennifer Good President and Chief Executive Officer | 434,615 | 144,900 | 0 | 0 | 8,400 | 2,810,719 |
2021-04-27 | 2020 | Thomas Sciascia Chief Medical Officer | 368,577 | 99,725 | 0 | 0 | 7,948 | 709,894 |
2021-04-27 | 2019 | Thomas Sciascia Chief Medical Officer | 339,311 | 81,475 | 0 | 0 | 7,542 | 786,845 |
2021-04-27 | 2020 | Chris Seiter | 357,115 | 99,288 | 0 | 0 | 6,700 | 716,218 |
2021-04-27 | 2020 | Yann Mazabraud Former Chief Commercial Officer and Head of International | 302,388 | 0 | 0 | 0 | 141,883 | 716,856 |
2021-04-27 | 2019 | Yann Mazabraud Former Chief Commercial Officer and Head of International | 325,736 | 83,868 | 0 | 0 | 146,545 | 914,666 |
2020-04-29 | 2019 | Thomas Sciascia, M.D. | 339,311 | 81,475 | 0 | 0 | 7,542 | 786,845 |
2020-04-29 | 2018 | Yann Mazabraud Chief Commercial Officer and Head of International | 185,317 | 35,162 | 0 | 0 | 221,187 | 1,012,833 |
2020-04-29 | 2019 | Yann Mazabraud Chief Commercial Officer and Head of International | 325,736 | 83,868 | 0 | 0 | 146,545 | 914,666 |
2020-04-29 | 2018 | Jennifer Good President and Chief Executive Officer | 400,000 | 120,000 | 0 | 0 | 8,250 | 528,250 |
2020-04-29 | 2019 | Jennifer Good President and Chief Executive Officer | 434,615 | 144,900 | 0 | 0 | 8,400 | 2,810,719 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.